Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.